RxSight (RXST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 annual meeting or until successors are elected and qualified.
Advisory vote to approve compensation of named executive officers as disclosed in the 2025 Summary Compensation Table.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends voting for all three director nominees: William J. Link, Ph.D., Robert Warner, and Shweta Singh Maniar.
Executive compensation and say-on-pay
Advisory vote on executive compensation for named executive officers is included as Proposal 2.
Partial view of Summaries dataset, powered by Quartr API
Latest events from RxSight
- Collaboration and innovation offset Q2 headwinds, supporting revised 2026 outlook and margin gains.RXST
Investor update7 Jul 2026 - Adjustable IOLs deliver superior outcomes and drive strong growth, supported by global expansion.RXST
Investor presentation7 Jul 2026 - Premium IOL growth continues, with LAL adoption and global expansion driving long-term gains.RXST
Stifel 2026 Virtual Ophthalmology Forum27 May 2026 - Adjustable lens technology drives superior outcomes, rapid growth, and global expansion.RXST
Corporate presentation14 May 2026 - Stable Q1 results and ongoing commercial initiatives support sequential growth and global expansion.RXST
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue fell 18.5% to $30.9M, but gross margin rose to 76.1% and guidance was reaffirmed.RXST
Q1 20266 May 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor, with strong governance.RXST
Proxy filing28 Apr 2026 - Premium lens adoption grows as utilization deepens and international expansion accelerates.RXST
25th Annual Needham Virtual Healthcare Conference16 Apr 2026 - 2025 LAL sales rose 12%, but total revenue fell 4% as LDD sales dropped sharply.RXST
Q4 202525 Feb 2026